Pfizer (PFE)
(Delayed Data from NYSE)
$29.42 USD
-0.24 (-0.81%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $29.44 +0.02 (0.07%) 4:42 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PFE 29.42 -0.24(-0.81%)
Will PFE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Other News for PFE
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
EU pharma committee takes positive view on AbbVie, Merck, others
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer, BioNTech announce CHMP recommendation for COVID-19 vaccine
Pfizer, BioNTech receive positive CHMP opinion for Omicron COVID-19 vaccine